- About Us
- Advisory Board
- Editorial
- Contact Us
- Advertise
- Contact MJH LS
- Do Not Sell My Information
- Terms and Conditions
- Privacy
© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Cleveland Clinic
Cleveland Clinic is a nonprofit, multispecialty academic medical center integrating outpatient and hospital care with research and education for better patient outcomes and experience. More than 4,500 staff physicians and researchers provide services through 20 patient-centered institutes. Cleveland Clinic is a 6,500-bed healthcare system with a main campus in Cleveland, 22 hospitals and over 220 outpatient locations. The health system includes five hospitals in Southeast Florida with more than 1,000 beds, a medical center for brain health in Las Vegas, a sports and executive health center in Toronto, and a 364-bed hospital in Abu Dhabi. Cleveland Clinic London, a 184-bed hospital, opened in March 2022. Cleveland Clinic is currently ranked as one of the nation’s top hospitals by U.S. News & World Report.
Connect with us:
Latest from Cleveland Clinic
New Phase 2 Data of IMU-838 Confirms Long-Term Benefits, Safety in Relapsing Multiple Sclerosis
June 21, 2022
Article
After 24 weeks of treatment, the adjusted mean annualized relapse rates were 0.53 with placebo vs 0.39 and 0.48 for the 30- and 45-mg groups of IMU-838.
Final Thoughts and Takeaways on MS DMT Discontinuation
June 12, 2022
Video
Robert Fox, MD, who presented the DISCO-MS study results at the CMSC 2022 Annual Meeting, offered his closing thoughts on the data and the take-home messaging for clinicians.
The DISCO-MS Study Findings and Clinical Experience
June 11, 2022
Video
Robert Fox, MD, offered perspective on data from the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis and how it compares with day-to-day clinical practice.
Hypothesis and Reasoning of the DISCO-MS Study
June 10, 2022
Video
Robert Fox, MD, shared the details of the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis, presented at the CMSC 2022 Annual Meeting.
Moderate-to-Severe Post-COVID-19 Sleep Disturbances Common, Especially in Black Individuals
June 08, 2022
Article
Patients with moderate-severe compared with normal-to-mild sleep disturbances had worse GAD-2 questionnaire scores, PHQ-2 scores, and PROMIS fatigue scores with no difference in age, sex, or hospitalization due to COVID-19.
Unanswered Questions About MS Stem Cell Transplantation
June 07, 2022
Video
Jeffrey Cohen, MD, spoke about the topic of his CMSC Presidential Lecture at the 2022 annual meeting, stem cell transplantation in multiple sclerosis, and what questions remain unanswered in this realm of treatment.